ArticleFrontiers in endocrinology2026
The relationship between pituitary size and the response to recombinant human growth hormone therapy in children with isolated growth hormone deficiency.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growth hormone deficiency (GHD) is one of the major endocrine causes of short stature in childhood. Pituitary size may reflect growth hormone secretory capacity; and children with hypoplastic pituitary exhibit more severe GHD. Given this relationship, pituitary size may also serve as a valuable predictor of the growth response to recombinant human growth hormone (rhGH) therapy. This study aimed to investigate the relationship between pituitary height and volume measured on MRI and the growth response to rhGH therapy in children with GHD. Methods: This retrospective, single-center study included 52 children with isolated GHD. Pretreatment pituitary MRI was evaluated for pituitary height and volumetric assessment. Two different methods were used to estimate pituitary volume: the classical ellipsoid formula and and the cross-sectional area. Pituitary volume SDS values were calculated according to age- and sex. Growth response to therapy was measured using height velocity (HV), HV SDS, ΔHeight SDS (change in height SDS between baseline and the end of the first year of the treatment), and ΔIGF1 SDS (change in IGF1 SDS between baseline and the end of the first year of the treatment). Results: The median age of the patients at diagnosis was 8.1 years (IQR: 4.4-11.4). At diagnosis, patients showed marked growth failure with a median height SDS of -2.84 (IQR: -3.65 to -2.44). Statistically significant negative correlation was observed between pituitary height and both ΔHeight SDS and ΔIGF1 SDS. Pituitary volume calculated by the ellipsoid method showed statistically significant negative correlations with HV, HV SDS, and ΔHeight SDS at the end of the first year of rhGH therapy (p < 0.05). Pituitary volume calculated by the cross-sectional area method only showed statistically significant negative correlation with HV SDS. When patients were categorized based on their response to rhGH therapy, those in the good-response group (HV SDS > 2) had significantly lower pituitary volume SDS calculated by the ellipsoid method compared to poor responders (p = 0.021). Conclusions: Our findings indicate that smaller pituitary size is associated with a more favorable growth response to rhGH therapy in children with isolated GHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.